Regulatory scrutiny of Johnson & Johnson (NYSE:JNJ) intensified as the FTC filed an amicus brief accusing the company of anticompetitive drug practices, even as J&J reported promising trial results for its investigational antibody IMAAVY (nipocalimab) in generalized myasthenia gravis, a development that could reshape its product outlook.
Previous Week Recap
- FTC Amicus Brief Targets J&J Monopoly: FTC filed an amicus brief in an antitrust case alleging Johnson & Johnson held a monopoly via anticompetitive drug practices; filing highlights regulatory scrutiny of JNJ’s market conduct.
- JNJ Positive IMAAVY Trial Results: Johnson & Johnson reported positive trial results for investigational antibody IMAAVY (nipocalimab) in generalized myasthenia gravis; data presented at EAN 2026 may affect future JNJ product outlook.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.